New Products
Thermo Electron announced last week the expansion of its HeavyPeptide AQUA product line. The HeavyPeptide AQUA kits can now be prepared with covalent modifications, such as phosphorylation, which are chemically identical to naturally occurring post-translational modifications.
Phosphorylation modification is now also available on Thermo's HeavyPeptide BASIC platform for high-throughput, pre-quantitative screening, and relative quantification.
Bruker Daltonics launched this week its Clinprot Forum an online forum moderated by Bruker application scientists that is available for all Bruker Daltonics customers at http://clinprot.bdal.de.
The discussion forum covers various aspects of clinical proteomics, such as biofluid profiling and validation, biomarker identification, the MALDI Molecular Imager, and the MALDI BioTyper for microorganism identification. It is designed to facilitate efficient information exchange and to stimulate the formation of research collaborations between different laboratories, Bruker said. Discussion threads include topics like sample preparation, standardization, biomarker identification, and bioinformatics methods.
Movers & Shakers
Gary Blackburn has become president and chief executive officer of Ohmx, the Evanston, Ill.-based protein biosensor company said on Monday. Most recently, he was director of research and technology at Motorola Clinical Micro Sensors.
Nicholas Cozzarelli, editor in chief of PNAS and a professor of molecular and cell biology at the University of California, Berkeley, died on March 19 from complications of treatment for Burkitt's lymphoma. He was 67. Cozzarelli received an undergraduate degree in biology from Princeton University and a PhD in biochemistry from Harvard Medical School.
Nicholas Ventresca has become corporate senior vice president of information technology as well as chief information officer of Charles River Laboratories, the company said last week. Prior to joining Charles River Labs, Ventresca was vice president in business technology for Pfizer's corporate headquarters in New York and R&D headquarters in New London, Conn.